

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>E&amp;Investment, Inc.</u>  (Last) (First) (Middle) C/O NEUROBO PHARMACEUTICALS, INC 177 HUNTINGTON AVENUE, SUITE 1700  (Street) BOSTON MA 02115  (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 12/30/2019	3. Issuer Name and Ticker or Trading Symbol <u>NeuroBo Pharmaceuticals, Inc. [ NRBO ]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year)  6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	4,335,800	I	Held by The E&Healthcare Investment Fund II <sup>(1)(4)</sup>
Common Stock	1,121,190	I	Held by The E&Healthcare Investment Fund No. 6 <sup>(2)(4)</sup>
Common Stock	1,864,799	I	Held by The E&Healthcare Investment Fund No. 7 <sup>(3)(4)</sup>

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			

**Explanation of Responses:**

- These shares are owned directly by The E&Healthcare Investment Fund II, a 10% owner of the Issuer, and indirectly by E&Investment, Inc., as sole general partner of The E&Healthcare Investment Fund II.
- These shares are owned directly by The E&Healthcare Investment Fund No. 6, and indirectly by E&Investment, Inc., as sole general partner of The E&Healthcare Investment Fund No. 6
- These shares are owned directly by The E&Healthcare Investment Fund No.7, a 10% owner of the Issuer, and indirectly by E&Investment, Inc., as sole general partner of The E&Healthcare Investment Fund No.7.
- E&Investment, Inc. disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.

**Remarks:**

Exhibit 24 - Power of Attorney

/s/ E&Investment, Inc., By: Na Yeon Kim, CEO 01/09/2020

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

**POWER OF ATTORNEY**

Know all by these present, that the undersigned hereby constitutes and appoints each of Jeong Gu (Richard) Kang and Amy Rabourn, signing singly, with full power of substitution, the undersigned's true and lawful attorney-in-fact to:

- (1) execute for and on behalf of the undersigned, forms and authentication documents for EDGAR Filing Access;
- (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such forms and authentication documents;
- (3) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director and/or 10% shareholder of NeuroBo Pharmaceuticals, Inc. (the "**Company**"), Forms 3, 4 and 5 in accordance with Section 16(a), and Schedules 13D and 13G in accordance with Section 13, of the Securities Exchange Act of 1934 and the rules thereunder;
- (4) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5 and Schedules 13D and 13G and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and
- (5) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interests of, or legally required by the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 and Schedules 13D and 13G with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed 9th day of January 2020.

/s/ Sun Dae Kang  
Signature

Sun Dae Kang  
Print Name